Skip to main content

NASDAQ:MBOT - Microbot Medical Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $20.00
  • Forecasted Upside: 184.09 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$7.04
▲ +0.01 (0.14%)
1 month | 3 months | 12 months
Get New Microbot Medical Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MBOT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MBOT

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$20.00
▲ +184.09% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Microbot Medical in the last 3 months. The average price target is $20.00, with a high forecast of $20.00 and a low forecast of $20.00. The average price target represents a 184.09% upside from the last price of $7.04.

Buy

The current consensus among 1 polled investment analysts is to buy stock in Microbot Medical. This rating has held steady since July 2019, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/17/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/15/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/15/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/13/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/11/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/9/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/10/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/10/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/18/2020HC WainwrightBoost Price TargetPositive ➝ Buy$19.00 ➝ $20.00Medium
i
Rating by Ram Selvaraju at HC Wainwright
5/20/2020HC WainwrightReiterated RatingBuy$19.00Low
i
Rating by Ram Selvaraju at HC Wainwright
5/1/2020HC WainwrightReiterated RatingBuy$26.00 ➝ $19.00Low
i
Rating by Ram Selvaraju at HC Wainwright
1/13/2020HC WainwrightBoost Price TargetBuy$12.00 ➝ $26.00High
i
Rating by Ram Selvaraju at HC Wainwright
12/24/2019HC WainwrightReiterated RatingPositive ➝ Buy$10.00 ➝ $12.00High
i
Rating by Ram Selvaraju at HC Wainwright
11/22/2019HC WainwrightReiterated RatingBuy$10.00Low
i
Rating by Ram Selvaraju at HC Wainwright
9/11/2019HC WainwrightReiterated RatingBuy$10.00Medium
i
Rating by Ram Selvaraju at HC Wainwright
8/21/2019HC WainwrightReiterated RatingBuy$10.00Low
i
Rating by R. Selvaraju at HC Wainwright
7/22/2019HC WainwrightInitiated CoverageBuy$10.00High
i
Rating by R. Selvaraju at HC Wainwright
11/19/2018LADENBURG THALM/SH SHDowngradeBuy ➝ Hold$1.75High
i
Rating by Jeffrey Cohen at LADENBURG THALM/SH SH
1/31/2018LADENBURG THALM/SH SHInitiated CoverageBuy ➝ Buy$1.75Low
i
11/18/2016S&P Equity ResearchLower Price TargetN/A
i
10/6/2016S&P Equity ResearchBoost Price Target$1.07 ➝ $1.20N/A
i
9/14/2016S&P Equity ResearchLower Price Target$1.57 ➝ $1.31N/A
i
8/16/2016S&P Equity ResearchLower Price Target$1.77 ➝ $0.45N/A
i
6/24/2016S&P Equity ResearchLower Price Target$0.39 ➝ $0.33N/A
i
6/17/2016S&P Equity ResearchLower Price Target$0.42 ➝ $0.35N/A
i
5/31/2016Maxim GroupDowngradeBuy ➝ HoldN/A
i
Rating by Jason Kolbert at Maxim Group
5/11/2016S&P Equity ResearchLower Price Target$3.59 ➝ $2.99N/A
i
5/10/2016Rodman & RenshawReiterated RatingBuyN/A
i
Rating by Ram Selvaraju at Rodman & Renshaw
(Data available from 5/10/2016 forward)
Microbot Medical logo
Microbot Medical Inc., a pre-clinical medical device company, researches, designs, and develops micro-robotics assisted medical technologies targeting the minimally invasive surgery space. The company, through its ViRob, TipCAT, and Liberty micro-robotic technologies, developing Self Cleaning Shunt for the treatment of hydrocephalus and normal pressure hydrocephalus; a disposable self-propelled locomotive device to treat capabilities within tubular lumens, such as the blood vessels, respiratory, and the urinary and GI tracts; a combination of a guidewire and microcatheter technologies that are used for endoluminal surgery; and maneuver guidewire, microcatheters, and over-the-wire devices within the body's vasculature. It has 42 issued/allowed patents and 23 patent applications pending worldwide. Microbot Medical Inc. was founded in 2010 and is based in Hingham, Massachusetts.
Read More

Today's Range

Now: $7.04
$6.90
$7.13

50 Day Range

MA: $7.93
$6.95
$8.89

52 Week Range

Now: $7.04
$6.03
$12.20

Volume

344 shs

Average Volume

149,456 shs

Market Capitalization

$50.04 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.98

Frequently Asked Questions

What sell-side analysts currently cover shares of Microbot Medical?

The following Wall Street analysts have issued stock ratings on Microbot Medical in the last twelve months: HC Wainwright, and Zacks Investment Research.
View the latest analyst ratings for MBOT.

What is the current price target for Microbot Medical?

1 Wall Street analysts have set twelve-month price targets for Microbot Medical in the last year. Their average twelve-month price target is $20.00, suggesting a possible upside of 184.1%. HC Wainwright has the highest price target set, predicting MBOT will reach $20.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $20.00 for Microbot Medical in the next year.
View the latest price targets for MBOT.

What is the current consensus analyst rating for Microbot Medical?

Microbot Medical currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MBOT will outperform the market and that investors should add to their positions of Microbot Medical.
View the latest ratings for MBOT.

What other companies compete with Microbot Medical?

How do I contact Microbot Medical's investor relations team?

Microbot Medical's physical mailing address is 25 RECREATION PARK DRIVE UNIT 108, HINGHAM MA, 02043. The biotechnology company's listed phone number is 781-875-3605 and its investor relations email address is [email protected] The official website for Microbot Medical is www.microbotmedical.com.